Codiak Biosciences Inc. (CDAK) PT Raised to $34 at Wedbush, Following Earnings
- Wall Street falls as Amazon earnings disappoint
- Amazon (AMZN) Plunges After Missing Sales and Guidance Expectations, Analysts Slash PTs to Reflect Weaker Guidance
- Pinterest (PINS) Tops Profit and Sales Views, But Shares Plunges Over 20% on a Big Monthly User Miss to Prompt Two Downgrades
- Bullard: Fed should taper this fall, go "fairly rapidly" to end early 2022
- Qualtrics International (XM) to Acquire Clarabridge
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Wedbush analyst David Nierengarten raised the price target on Codiak Biosciences Inc. (NASDAQ: CDAK) to $34.00 (from $31.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerner (CERN) PT Raised to $87 at Cantor Fitzgerald Following Earnings
- Avient Corp. (AVNT) PT Raised to $65 at Oppenheimer, Following Earnings
- Champion Iron Ltd. (CIA:CN) (CIAFF) PT Raised to Cdn$8.50 at TD Securities
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!